GLP-1 receptor agonists nearly doubled the rate of prediabetes reversal to normal blood sugar and reduced new diabetes onset by 72% compared to lifestyle modification alone.
72% diabetes preventionGLP-1 receptor agonists reduced the risk of prediabetic patients developing diabetes by 72% compared to lifestyle modification alone
What the researchers found
GLP-1RAs significantly increased prediabetes reversion to normoglycemia (RR 1.76, 95% CI 1.45–2.13, p < 0.00001) and prevented new-onset diabetes (RR 0.28, 95% CI 0.19–0.43, p < 0.00001). Significant reductions were also seen in HbA1c, fasting plasma glucose, body weight, waist circumference, triglycerides, and LDL cholesterol (all p < 0.05). Gastrointestinal disorders were more common with GLP-1RAs.
Why it matters
Prediabetes affects hundreds of millions worldwide and usually progresses to full diabetes over time. While lifestyle changes help, they're often insufficient. This meta-analysis provides the strongest evidence yet that GLP-1 drugs can actually reverse prediabetes — not just slow its progression — potentially preventing diabetes altogether.
The numbers in context
GLP-1RAs were previously only evaluated as secondary and exploratory outcomes with limited sample sizes in prediabetes populations.
How the study worked
Systematic review and meta-analysis of 12 randomized controlled trials identified from Web of Science, SCOPUS, PubMed, and Cochrane. Included 2,903 patients in GLP-1RA groups and 1,413 in control groups. Quality assessed using Cochrane Risk of Bias Tool. Evidence certainty evaluated using GRADE framework.
Who was studied
Adults with prediabetes from randomized controlled trials
What this study cannot tell us
Evidence for prediabetes reversion was rated low quality by GRADE. Diabetes prevention evidence was moderate quality. Studies had varying follow-up periods. GLP-1RA types and doses varied across trials. Higher gastrointestinal side effects may limit adherence. Cost-effectiveness not assessed.
How to read the evidence
Rated moderate: meta-analysis of 12 RCTs with over 4,300 patients, though evidence quality for the reversal outcome was rated low by GRADE and diabetes prevention was moderate.
When this study was published
Published in 2024 with literature search through May 2023. Represents the most comprehensive analysis of GLP-1 drugs specifically for prediabetes.
The bigger picture
If GLP-1 drugs can prevent diabetes by reversing prediabetes, they could shift the paradigm from treating diabetes to preventing it. This has enormous public health implications given that prediabetes affects an estimated 720 million adults worldwide.
Questions still open
- Which specific GLP-1 drug is most effective for preventing diabetes progression?
- Do the diabetes prevention benefits persist after stopping GLP-1 treatment?
- Would early GLP-1 treatment be cost-effective compared to treating diabetes later?
Common questions
Can GLP-1 drugs reverse prediabetes?
Should prediabetic patients take GLP-1 medications?
Read the original research
Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials.
Diabetology & metabolic syndrome, 16(1), 129
Citation
Salamah, Hazem Mohamed; Marey, Ahmed; Abugdida, Mohamed; Abualkhair, Khaled Alsayed; Elshenawy, Salem; Elhassan, Wael Atif Fadl; Naguib, Mostafa Mahmoud; Malnev, Dmitrii; Durrani, Jamrose; Bailey, Ronelle; Tsyunchyk, Anastasiia; Ibrahim, Lena; Zavgorodneva, Zhanna; Sherazi, Andleeb. (2024). Efficacy and safety of glucagon-like peptide-1 receptor agonists on prediabetes: a systematic review and meta-analysis of randomized controlled trials.. Diabetology & metabolic syndrome, 16(1), 129. https://doi.org/10.1186/s13098-024-01371-3